Company profile
Trevena, Inc.
OTC: TRVN · Healthcare · Biotechnology
#926 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 38GM —SS 34
v0.1 · 25/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ market scale, operating margin
Methodology →Revenue TTM
$547.0k
Rev growth YoY (TTM)
-82.9%
Net income (FY)
-$40.3M
Employees
23
as of 2026-08-31
Market cap
$864
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$567.0k$567.0k2021
Net income-$40.3M-$40.3M2023
Operating income-$35.3M-$35.3M2023
Total assets$40.6M$40.6M2023
Liabilities$48.3M$48.3M2023
Equity-$7.7M-$7.7M2023
Revenue trend
FY2018 – FY2021 · USD
FY18
FY18
FY19
FY19
FY19
FY19
FY20
FY21
Revenue by segment
Filed disclosures · FY2023
By product
License and royalty revenues50%
License revenue47%
Royalty revenue3%
By geography
Not disclosed.
The read
What is Trevena, Inc.’s revenue?
Trevena, Inc. booked $567.0k in FY2021 revenue, contracting 82% year over year — slower than 88% of Healthcare companies we track, at a -7105.6% net margin.
Peers · Healthcare
Ernexa Therapeutics Inc.43DViropro Inc.——VYNE Therapeutics Inc.38DSolana Company49DCardax, Inc.——Lipella Pharmaceuticals Inc.——Neighbors
Chester →Key facts
CEOCarrie L. Bourdow
SectorHealthcare
IndustryBiotechnology
HeadquartersChesterbrook, PA
ExchangeOTC: TRVN
Employees23
IPO date2014-01-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.